Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.

Vivek Subbiah: The evidence for different approaches to colorectal cancer screening is reviewed and a framework for evaluation of screening programs going forward is proposed.

Nitin Jain: Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL.

Oscar Arrieta: We publish an update on the multidisciplinary management of TKI-induced diarrhea.

Pernille Bidstrup: How should parents and health care professionals talk about the child’s cancer disease and treatment?

Vivek Subbiah: Adding chemotherapy to cemiplimab at progression might provide a new second-line treatment for patients with advanced non-small-cell lung cancer.

Arya Roy: Our new article: Oncotype Dx score and HER2- low expression in breast cancer published in Cancers MDPI!

Bishal Gyawali: Congratulations to Dr. Abhenil Mittal and our Queen’s University Department of Oncology resident Dr. Kristin Wright on the publication of this important paper.

Ishwaria Subbiah: Nearly 1 in 3 physicians with the HIGHEST possible resilience score still had burnout!

Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.